MS-1819
- Generic Name
- MS-1819
- Drug Type
- Biotech
- Unique Ingredient Identifier
- V6AP1D8NNW
- Background
MS-1819 is under investigation in clinical trial NCT03481803 (A Phase IIa Study With Escalating Dose of MS1819-SD).
Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic Fibrosis
- Conditions
- Cystic FibrosisExocrine Pancreatic Insufficiency
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT05719311
- Locations
- 🇺🇸
The Cystic Fibrosis Institute, Northfield, Illinois, United States
🇺🇸Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸Childrens Lung Specialists, Las Vegas, Nevada, United States
OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
- Conditions
- Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)
- Interventions
- Drug: Porcine PERT
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT04375878
- Locations
- 🇺🇸
Investigator Site 102, Altamonte Springs, Florida, United States
🇺🇸Investigator Site 111, Wichita, Kansas, United States
🇺🇸Investigator Site 106, Hershey, Pennsylvania, United States
Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs
- Conditions
- Cystic FibrosisCystic Fibrosis of PancreasCystic Fibrosis Gastrointestinal Disease
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- AzurRx SAS
- Target Recruit Count
- 20
- Registration Number
- NCT04302662
- Locations
- ðŸ‡ðŸ‡º
Tüdőgyógyintézet Törökbálint Gyermekpulmonológiai Osztály és Szakrendelés, Törökbálint, Hungary
ðŸ‡ðŸ‡ºBorsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Gyermekegészségügyi Központ, Miskolc, Hungary
ðŸ‡ðŸ‡ºOrszágos Korányi TBC és Pulmonológiai Intézet Cisztás Fibrózis Részleg, Budapest, Hungary
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
- Conditions
- Exocrine Pancreatic Insufficiency (EPI)Cystic Fibrosis (CF)
- Interventions
- Drug: Porcine PERT
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Entero Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03746483
- Locations
- 🇺🇸
Investigator Site 105, Long Beach, California, United States
🇺🇸Investigator Site 102, Altamonte Springs, Florida, United States
🇺🇸Investigator Site 108, Portland, Maine, United States
A Phase IIa Study With Escalating Dose of MS1819-SD
- Conditions
- Chronic PancreatitisDistal Pancreatectomy
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- AzurRx SAS
- Target Recruit Count
- 11
- Registration Number
- NCT03481803
- Locations
- 🇦🇺
Mackay Institute of Research and Innovation, Mackay, Queensland, Australia
🇳🇿Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇦🇺Linear Research, Perth, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.